Neuberg Diagnostics to Invest ₹300 cr for Expansion
by Shrutee K/DNS
Mumbai, 12th March,2018 :- Neuberg Diagnostics, an
alliance of five leading pathology laboratories from India, South Africa and
the UAE, is planning to invest ₹300 crore in India, the
Middle East and Africa as part of its expansion plans. “We are looking at investing another ₹300 crore for expansion plans in the coming years, which will be
funded through internal accruals,” Neuberg Diagnostics Chairman GSK Velu said.
The company having focus on new generation technologies in the
diagnostics space, according to Velu, has already invested ₹450 crore in acquiring laboratories in India and abroad and
upgrading them. Neuberg at present has 50 labs and 500 centres in the South and
West India, and plans to increase the total count to 150 labs and 1,000 centres
in the next three years. “We will have three world class global reference laboratories
located in Bengaluru, Ahmedabad, and Durban (South Africa) carrying out
advanced range of testing using new generation in vitro diagnostics
techniques,” he said.
According to Velu, new generation technologies like genomics,
metabolomics and proteomics that provide accurate diagnosis and also
combination diagnostics, where hospitals, pharma companies and pathologists
work together, is the future of the diagnostics industry. “India is lagging behind in terms of technology and we wants to
focus in those areas,” he said.
An alliance of five top laboratories like Anand Diagnostic
Laboratory, Supratech Micropath, Ehrlich lab, Global labs and Minerva Labs, the
company plans to have three infrastructure models — global centre of
excellence, regional reference centres and satellite centres. It also wants to establish research centres in the US and European
markets, to get access to latest technologies and bring it to India, according
to Velu. “Talks are on with some universities and small labs in the
regions,” he said.
The company, which is growing at a compounded annual growth rate
of 15 per cent, clocked an consolidated revenue of ₹400 crore last year and hopes to cross ₹1,000-crore mark by 2021-22.
ReplyDeleteHey, thanks for the information. your posts are informative and useful. I am regularly following your posts.
Metropolis Healthcare,
Bayer Crop Sciences,
Bajaj Consumer,
United Spirits,
Varun Beverages,
Shriram Transport Finance,